


## EGFR/HER2-IN-8

<b>Cat. No.:</b>	HY-151161
<b>CAS No.:</b>	2820126-32-5
<b>Molecular Formula:</b>	C <sub>16</sub> H <sub>16</sub> N <sub>4</sub> O <sub>2</sub> S
<b>Molecular Weight:</b>	328.39
<b>Target:</b>	EGFR
<b>Pathway:</b>	JAK/STAT Signaling; Protein Tyrosine Kinase/RTK
<b>Storage:</b>	Please store the product under the recommended conditions in the Certificate of Analysis.



### BIOLOGICAL ACTIVITY

<b>Description</b>	EGFR/HER2-IN-8 (compound 34) is a EGFR/HER2 and DHFR inhibitor. EGFR/HER2-IN-8 inhibits EGFR kinase, HER2 kinase and DHFR with IC <sub>50</sub> s of 0.45, 0.244 and 5.669 μM, respectively. EGFR/HER2-IN-8 shows anticancer activity against several cancer cell lines with high safety profile and selectivity indices. EGFR/HER2-IN-8 can be used for the research of cancer <sup>[1]</sup> .								
<b>IC<sub>50</sub> &amp; Target</b>	IC <sub>50</sub> : 0.45 μM (EGFR kinase), 0.244 μM (HER2 kinase), 5.669 μM (DHFR) <sup>[1]</sup>								
<b>In Vitro</b>	<p>EGFR/HER2-IN-8 (0-100 μM; 72 h) shows highly potent anticancer activity to HepG2, MCF 7, HCT-116, PC-3 and Hela cell lines and exhibits selective cytotoxicity against cancer cell lines rather than normal cell line<sup>[1]</sup>.</p> <p>MCE has not independently confirmed the accuracy of these methods. They are for reference only.</p> <p>Cell Cytotoxicity Assay<sup>[1]</sup></p> <table border="1"> <tr> <td>Cell Line:</td> <td>HepG2 hepatocellular carcinoma, MCF 7 breast cancer, HCT-116 colorectal carcinoma, PC-3 prostate, Hea cervical epithelioid carcinoma cell lines and WI-38 fetal lung fibroblast cells</td> </tr> <tr> <td>Concentration:</td> <td>0-100 μM</td> </tr> <tr> <td>Incubation Time:</td> <td>72 hours</td> </tr> <tr> <td>Result:</td> <td>Exibited more potent cytotoxicity than SOR towards HepG2, MCF 7, HCT-116, PC-3 and Hela cell lines with IC<sub>50</sub>s of 7.34, 5.19, 9.23, 18.5 and 13.02 μM, respectively. Showed weak cytotoxic activity against WI-38 cell line with an IC<sub>50</sub> value of 67.25 μM, and possessed best selectivity indices towards MCF-7 breast cancer cell line.</td> </tr> </table>	Cell Line:	HepG2 hepatocellular carcinoma, MCF 7 breast cancer, HCT-116 colorectal carcinoma, PC-3 prostate, Hea cervical epithelioid carcinoma cell lines and WI-38 fetal lung fibroblast cells	Concentration:	0-100 μM	Incubation Time:	72 hours	Result:	Exibited more potent cytotoxicity than SOR towards HepG2, MCF 7, HCT-116, PC-3 and Hela cell lines with IC <sub>50</sub> s of 7.34, 5.19, 9.23, 18.5 and 13.02 μM, respectively. Showed weak cytotoxic activity against WI-38 cell line with an IC <sub>50</sub> value of 67.25 μM, and possessed best selectivity indices towards MCF-7 breast cancer cell line.
Cell Line:	HepG2 hepatocellular carcinoma, MCF 7 breast cancer, HCT-116 colorectal carcinoma, PC-3 prostate, Hea cervical epithelioid carcinoma cell lines and WI-38 fetal lung fibroblast cells								
Concentration:	0-100 μM								
Incubation Time:	72 hours								
Result:	Exibited more potent cytotoxicity than SOR towards HepG2, MCF 7, HCT-116, PC-3 and Hela cell lines with IC <sub>50</sub> s of 7.34, 5.19, 9.23, 18.5 and 13.02 μM, respectively. Showed weak cytotoxic activity against WI-38 cell line with an IC <sub>50</sub> value of 67.25 μM, and possessed best selectivity indices towards MCF-7 breast cancer cell line.								

### REFERENCES

[1]. Sabry MA, et al. New thiazole-based derivatives as EGFR/HER2 and DHFR inhibitors: Synthesis, molecular modeling simulations and anticancer activity. Eur J Med Chem. 2022 Aug 10;241:114661.

---

**Caution: Product has not been fully validated for medical applications. For research use only.**

Tel: 609-228-6898

Fax: 609-228-5909

E-mail: [tech@MedChemExpress.com](mailto:tech@MedChemExpress.com)

Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA